Friday 6 November 2026 Export RDY’s income statement to Excel — free account

Dr. Reddy's Laboratories Ltd

RDY Healthcare Drug Manufacturers Specialty & Generic

Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025.

Revenue: −10.1%
EPS: −36.8%
Free cash flow: −70.5%
Total debt: +14.1%

Quarter to September 2026, against a year earlier

14.86 0.33 +2.27%

Follow RDY

Alert me

Market cap: $12.1B
P/E: 45.4×
Fwd P/E: 30.7×
Dividend yield: 0.00%
F-score: 4/9
Altman Z: 5.26
Beneish M: −2.59
Dividend safety: 74/100

Overview

Dr. Reddy's Laboratories Ltd (RDY) P/E ratio

Alert me on P/E ratio

As of 6 November 2026, Dr. Reddy's Laboratories Ltd (RDY) trades at a P/E ratio of 45.4×. Over the past ten years it has ranged from 15.9× (October 2019) to 58.5× (December 2020); the current reading is higher than 91% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 20.5× and above the Healthcare sector median of 24.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/RDY/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Dr. Reddy&#39;s Laboratories Ltd P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/RDY/metrics/pe-ratio">Dr. Reddy&#39;s Laboratories Ltd (RDY) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2026	25.8×	29.03%
FY2025	20.0×	9.18%
FY2024	18.3×	7.03%
FY2023	17.1×	(42.77%)
FY2022	29.9×	(30.57%)
FY2021	43.0×	74.94%
FY2020	24.6×	(2.31%)
FY2019	25.2×	(28.48%)
FY2018	35.2×	(4.39%)
FY2017	36.8×	42.86%

Period	P/E ratio	Change
Sep 2026	38.6×	5.73%
Jun 2026	36.5×	41.51%
Mar 2026	25.8×	41.42%
Dec 2025	18.2×	5.65%
43 more quarters	Free account

Against its own ten years

Low 15.9× High 58.5×

Ten-year median 25.8×

Current reading's percentile 90

Company	P/E ratio
VTRS Viatris Inc. compare	n/m
ELAN Elanco Animal Health Incorporated compare	n/m
ALKS Alkermes plc compare	n/m
UTHR United Therapeutics Corporation compare	19.6×
NBIX Neurocrine Biosciences, Inc. compare	23.6×
LNTH Lantheus Holdings, Inc. compare	24.3×
AMRX AMNEAL PHARMACEUTICALS, INC. compare	38.2×
RDY Dr. Reddy's Laboratories Ltd	45.4×
KNSA Kiniksa Pharmaceuticals International, plc compare	65.9×
Drug Manufacturers Specialty & Generic industry median	20.5×
Healthcare sector median	24.5×
Market median	17.8×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

Dr. Reddy's Laboratories Ltd (RDY) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on RDY

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on RDY

Stockrow Weekly